Participant Flow

Fig. 1. CONSORT figure representing enrolment data.



Baseline Characteristics

Characteristic	Group M (n=37)	Group C (n=37)
Age/year, $\bar{x}\pm s$	54.3±14.4	52.8±13.1
Female, *n* (%)	20 (54.1)	20 (54.1)
BMI/(kg·m^{-2}), $\bar{x}\pm s$	23.8±4.3	24.1±3.1
ASA, *n* (%)		
Ⅰ	4 (10.8)	3 (8.1)
Ⅱ	30 (81.1)	30 (81.1)
Ⅲ	3 (8.1)	4 (10.8)
Comorbidity, *n* (%)		
Hypertension	11 (29.7)	18 (48.6)
Diabetes mellitus	7 (18.9)	5 (13.5)
Hydronephrosis, *n* (%)	21 (56.8)	25 (67.6)
Preoperative risk factor, *n* (%)		
History of calculous pyelonephritis	27 (73.0)	22 (59.5)
Positive MSU culture[b]	15 (40.5)	12 (32.4)
Leucocyte count≥500/μL	18 (48.6)	19 (51.4)
Number of risk factor, *n* (%)		
1	21 (56.8)	22 (59.5)
2	9 (24.3)	14 (37.8)
3	7 (18.9)	1 (2.7)
Type of preoperative decompression, *n* (%)	22/7/4/4	27/6/2/2
None	22 (59.5)	27 (73.0)
Ureteral double-J tube	7 (18.9)	6 (16.2)
Percutaneous nephrostomy	4 (10.8)	2 (5.4)
Both[a]	4 (10.8)	2 (5.4)
Cumulative stone diameter/mm, *M (IQR)*	47 (27-29)	40 (23-68)
Operating time/min, $\bar{x}\pm s$	92.5±35.9	100.1±28.6
Residual stone, *n* (%)	6 (16.2)	4 (10.8)

a: Ureteral double-J tube and percutaneous nephrostomy. METH: Methylprednisolone; BMI: Body mass index; ASA:

American Society of Anesthesiologists; MSU: Mid-stream urine; *M* (*IQR*): Median (quartile range).

Outcome Measures

	Group M (n=37)	Group C (n=37)
Urosepsis (%)	2 (5.4)	9 (24.3)
females	2	7
Uroseptic shock (%)	0	4 (10.8)
females	0	4
SIRS (%)	7 (18.9)	19 (51.4)
females	5	12

Adverse Events

There were no adverse events associated with this trial.